← Eichor
Study identifier: NCT06596681 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain

Condition: Pain, Intractable  ·  Sponsor: Beijing Tiantan Hospital

PhaseEARLY_Phase 1
Planned participants6
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

Previous studies have shown that the anterior cingulate cortex is involved in the regulation of pain and its associated negative emotions, that pyramidal neurons are highly excitable in chronic neuropathic pain conditions, and that silencing of pyramidal neurons can eliminate pain. The aim of this study was to evaluate the safety, tolerability, and efficacy of intracranial injection of GA (containing the hM4Di gene) in the anterior cingulate cortex in combination with oral clozapine for the treatment of refractory neuropathic pain.

This description comes directly from the study's public registry record.

Talk to the study team

Yahui Zhu, Doctor  ·  13439182912  ·  zhuyahuidr@sina.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Tiantan HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06596681